This suggested that a specific PKC isoform, mainly the PKCα isoform, is responsible for the activation of NF-κB in bladder cancer, based on data using sotrastaurin, a general nonselective PKC inhibitor, versus Gö6976, which is more selective for PKCα/β [26]. Here, PRKCA is linked to urinary bladder carcinoma.